Related Experiment Video

Updated: Oct 25, 2025

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

9.9K

Risk of motor vehicle collisions after methadone use

Ya-Hui Yang1, Pei-Shan Ho2,3, Trong-Neng Wu4

  • 1Department of Health-Business Administration, Fooyin University, Kaohsiung, Taiwan.

Elife
|August 5, 2021
PubMed

Insights

Methadone maintenance treatment (MMT) may increase motor vehicle collision risk for opioid users. Road safety for MMT patients, especially within 90 days of treatment, requires attention.

Area of Science:

  • Addiction Medicine
  • Public Health
  • Traffic Safety

Background:

  • Opioid dependence is a significant public health issue.
  • Methadone maintenance treatment (MMT) is effective for opioid dependence but may pose risks.
  • The association between MMT and motor vehicle collision (MVC) risk is not well-established.

Purpose of the Study:

  • To estimate MVC incidence rates in opioid users receiving MMT.
  • To compare MVC risk between MMT patients and opioid users not on MMT.
  • To identify temporal patterns in MVC risk following MMT initiation.

Main Methods:

  • Population-based retrospective cohort study.
  • Frequency-matched controls (1:2 ratio) comparing MMT cases to non-MMT opioid users.
  • Data linkage across nationwide administrative registry databases (2009-2016).

Main Results:

  • MVC incidence rates were highest in adults on MMT, intermediate in general opiate users, and lowest in the general adult population.
  • Opioid users on MMT demonstrated significantly higher MVC incidence rates compared to those not on MMT.
  • Kaplan-Meier analysis revealed significantly different MVC incidence curves, with elevated risk observed within the first 90 days of MMT.

Conclusions:

  • Drivers receiving MMT exhibit a higher risk of motor vehicle collisions than opioid users not on MMT.
  • Road safety interventions and monitoring are crucial for MMT patients, particularly during the initial 90 days of treatment.
Keywords:
cohort studyhumanmedicinemethadone maintenance treatmentvehicle motor collision

More Related Videos

Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury07:07

Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury

Published on: February 10, 2020

10.8K
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.4K

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
548
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
430
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
37
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
832
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
495
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.7K